AdaptHealthAHCO
About: AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.
Employees: 10,700
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
185% more call options, than puts
Call options by funds: $156M | Put options by funds: $54.7M
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
83% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 53
18% more capital invested
Capital invested by funds: $1.17B [Q2] → $1.39B (+$217M) [Q3]
5% more funds holding
Funds holding: 205 [Q2] → 216 (+11) [Q3]
3.94% more ownership
Funds ownership: 88.12% [Q2] → 92.07% (+3.94%) [Q3]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
RBC Capital Ben Hendrix 29% 1-year accuracy 20 / 70 met price target | 5%upside $11 | Outperform Maintained | 19 Nov 2024 |
Truist Securities David Macdonald 59% 1-year accuracy 57 / 96 met price target | 14%upside $12 | Buy Maintained | 15 Nov 2024 |
UBS Whit Mayo 53% 1-year accuracy 9 / 17 met price target | 14%upside $12 | Buy Maintained | 6 Nov 2024 |
Canaccord Genuity Richard Close 59% 1-year accuracy 16 / 27 met price target | 24%upside $13 | Buy Maintained | 6 Nov 2024 |
Baird Eric Coldwell 36% 1-year accuracy 12 / 33 met price target | 33%upside $14 | Outperform Maintained | 6 Nov 2024 |